Medline
42.? Morrison J, Lu QL, Pastoret C, Partridge T, Bou-Gharios G. T-cell-dependent fibrosis in the mdx dystrophic mouse. Lab Invest 80: 881–891, 2000. Medline
43.? Nagler A, Firman N, Feferman R, Cotev S, Pines M, Shoshan S. Reduction in pulmonary fibrosis in vivo by halofuginone. Am J Respir Crit Care Med 154: 1082–1086, 1996. Abstract/FREE Full Text
44.? Nagler A, Genina O, Lavelin I, Ohana M, Pines M. Halofuginone, an inhibitor of collagen type I synthesis, prevents postoperative adhesion formation in the rat uterine horn model. Am J Obstet Gynecol 180: 558–563, 1999. CrossRef
Medline
45.? Nagler A, Gofrit O, Ohana M, Pode D, Genina O, Pines M. The effect of halofuginone, an inhibitor of collagen type I synthesis, on urethral stricture formation: in vivo and in vitro study in a rat model. J Urol 164: 1776–1780, 2000. CrossRef
Medline
46.? Nagler A, Rivkind AI, Raphael J, Levi-Schaffer F, Genina O, Lavelin I, Pines M. Halofuginone—an inhibitor of collagen type I synthesis—prevents postoperative formation of abdominal adhesions. Ann Surg 227: 575–582, 1998. CrossRef
Medline
47.? Neilan TG, Januzzi JL, Lee-Lewandrowski E, Ton-Nu TT, Yoerger DM, Jassal DS, Lewandrowski KB, Siegel AJ, Marshall JE, Douglas PS, Lawlor D, Picard MH, Wood MJ. Myocardial injury and ventricular dysfunction related to training levels among nonelite participants in the Boston marathon. Circulation 114: 2325–2333, 2006. Abstract/FREE Full Text
48.? Neilan TG, Jassal DS, Perez-Sanz TM, Raher MJ, Pradhan AD, Buys ES, Ichinose F, Bayne DB, Halpern EF, Weyman AE, Derumeaux G, Bloch KD, Picard MH, Scherrer-Crosbie M. Tissue Doppler imaging predicts left ventricular dysfunction and mortality in a murine model of cardiac injury. Eur Heart J 27: 1868–1875, 2006. Abstract/FREE Full Text
49.? Pastoret C, Sebille A. Age-related differences in regeneration of dystrophic (mdx) and normal muscle in the mouse. Muscle Nerve 18: 1147–1154, 1995. CrossRef
Medline
50.? Pastoret C, Sebille A. mdx mice show progressive weakness and muscle deterioration with age. J Neurol Sci 129: 97–105, 1995. CrossRef
Medline
51.? Pines M, Nagler A. Halofuginone: a novel antifibrotic therapy. Gen Pharmacol 30: 445–450, 1998. CrossRef
Medline
52.? Pines M, Snyder D, Yarkoni S, Nagler A. Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. Biol Blood Marrow Transplant 9: 417–425, 2003. CrossRef
Medline
53.? Quinlan JG, Hahn HS, Wong BL, Lorenz JN, Wenisch AS, Levin LS. Evolution of the mdx mouse cardiomyopathy: physiological and morphological findings. Neuromuscul Disord 14: 491–496, 2004. CrossRef
Medline
53a.? Ramunddal T, Lindbom M, Omerovic E. Native cardiac reserve predicts survival in acute post infarction heart failure in mice (Abstract). Cardiovasc Ultrasound 5: 46, 2007. CrossRef
Medline
54.? Sausbier M, Zhou XB, Beier C, Sausbier U, Wolpers D, Maget S, Martin C, Dietrich A, Ressmeyer AR, Renz H, Schlossmann J, Hofmann F, Neuhuber W, Gudermann T, Uhlig S, Korth M, Ruth P. Reduced rather than enhanced cholinergic airway constriction in mice with ablation of the large conductance Ca2+-activated K+ channel. FASEB J 21: 812–822, 2007. Abstract/FREE Full Text
56.? Sebag IA, Handschumacher MD, Ichinose F, Morgan JG, Hataishi R, Rodrigues AC, Guerrero JL, Steudel W, Raher MJ, Halpern EF, Derumeaux G, Bloch KD, Picard MH, Scherrer-Crosbie M. Quantitative assessment of regional myocardial
function in mice by tissue Doppler imaging: comparison with hemodynamics and sonomicrometry. Circulation 111: 2611–2616, 2005. Abstract/FREE Full Text
57.? Serini G, Bochaton-Piallat ML, Ropraz P, Geinoz A, Borsi L, Zardi L, Gabbiani G. The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1. J Cell Biol 142: 873–881, 1998. Abstract/FREE Full Text
58.? Sheffer Y, Leon O, Pinthus JH, Nagler A, Mor Y, Genin O, Iluz M, Kawada N, Yoshizato K, Pines M. Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy-mediated antitumoral effect. Mol Cancer Ther 6: 570–577, 2007. Abstract/FREE Full Text
59.? Skrabek RQ, Anderson JE. Metabolic shifts and myocyte hypertrophy in deflazacort treatment of mdx mouse cardiomyopathy. Muscle Nerve 24: 192–202, 2001. CrossRef
Medline
60.? Stansfield WE, Tang R, Moss NC, Baldwin AS, Willis MS, Selzman CH. Proteasome inhibition promotes regression of left ventricular hypertrophy. Am J Physiol Heart Circ Physiol 294: H645–H650, 2008. Abstract/FREE Full Text
61.? Stedman HH, Sweeney HL, Shrager JB, Maguire HC, Panettieri RA, Petrof B, Narusawa M, Leferovich JM, Sladky JT, Kelly AM. The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 352: 536–539, 1991. CrossRef
Medline
62.? Sweat F, Puchtler H, Rosenthal SI. Sirius Red F3BA as a stain for connective tissue. Arch Pathol 78: 69–72, 1964. Medline
63.? Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 3: 349–363, 2002. CrossRef
Medline
64.? Von der Mark K. Localization of collagen types in tissues. Int Rev Connect Tissue Res 9: 265–324, 1981. Medline
65.? Wess L, Eastwood MA, Wess TJ, Busuttil A, Miller A. Cross linking of collagen is increased in colonic diverticulosis. Gut 37: 91–94, 1995. Abstract/FREE Full Text
66.? Wozniak AC, Anderson JE. Nitric oxide-dependence of satellite stem cell activation and quiescence on normal skeletal muscle fibers. Dev Dyn 236: 240–250, 2007. CrossRef
Medline
67.? Yang J, Liu Y. Delayed administration of hepatocyte growth factor reduces renal fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol 284: F349–F357, 2003. Abstract/FREE Full Text
Переведено проектом МОЙМИО:
www.mymio.org
Оригинал статьи: http://ajpheart. physiology. org/content/294/4/H1550.full
|
Из за большого объема этот материал размещен на нескольких страницах:
1 2 3 4 5 |
